Profile data is unavailable for this security.
About the company
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).
- Revenue in USD (TTM)43.38m
- Net income in USD-123.40m
- Incorporated2020
- Employees140.00
- LocationTango Therapeutics Inc201 Brookline Avenue, Suite 901BOSTON 02215United StatesUSA
- Phone+1 (857) 320-4900
- Fax+1 (302) 636-5454
- Websitehttps://www.tangotx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProQR Therapeutics NV | 22.21m | -24.94m | 383.37m | 157.00 | -- | 11.72 | -- | 17.26 | -0.3059 | -0.3059 | 0.2724 | 0.3089 | 0.1713 | -- | -- | 141,438.90 | -19.24 | -35.51 | -26.22 | -40.51 | -- | -- | -112.31 | -926.31 | -- | -- | 0.4105 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Prime Medicine Inc | 800.00k | -219.25m | 384.10m | 234.00 | -- | 2.21 | -- | 480.12 | -2.05 | -2.05 | 0.0073 | 1.44 | 0.0028 | -- | -- | 3,418.80 | -76.67 | -- | -88.64 | -- | -- | -- | -27,406.13 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Alector Inc | 61.51m | -158.41m | 385.85m | 241.00 | -- | 3.24 | -- | 6.27 | -1.71 | -1.71 | 0.6607 | 1.21 | 0.1035 | -- | -- | 252,082.00 | -26.66 | -20.00 | -35.58 | -23.81 | -- | -- | -257.54 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Sangamo Therapeutics Inc | 52.29m | -134.84m | 391.45m | 405.00 | -- | 10.02 | -- | 7.49 | -0.7079 | -0.7079 | 0.2696 | 0.1876 | 0.316 | -- | 8.98 | 129,113.60 | -81.48 | -26.09 | -112.69 | -31.04 | -- | -- | -257.86 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Larimar Therapeutics Inc | 0.00 | -64.77m | 393.05m | 42.00 | -- | 1.98 | -- | -- | -1.15 | -1.15 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -40.11 | -42.22 | -43.16 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| 4D Molecular Therapeutics Inc | 18.00k | -143.48m | 404.84m | 201.00 | -- | 0.7325 | -- | 22,491.28 | -2.76 | -2.76 | 0.0004 | 10.63 | 0.00004 | -- | -- | 122.45 | -29.72 | -32.67 | -31.26 | -34.90 | -- | -- | -797,111.10 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Akebia Therapeutics Inc | 169.88m | -45.99m | 410.18m | 167.00 | -- | -- | -- | 2.41 | -0.2207 | -0.2207 | 0.8338 | -0.2383 | 0.7684 | 1.33 | 6.20 | 1,017,240.00 | -20.80 | -37.42 | -31.00 | -56.00 | 84.79 | 69.13 | -27.07 | -82.25 | 1.21 | -2.52 | -- | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Verve Therapeutics Inc | 24.40m | -197.03m | 410.62m | 255.00 | -- | 0.8072 | -- | 16.83 | -2.46 | -2.46 | 0.3033 | 6.01 | 0.0382 | -- | 8.45 | 95,670.59 | -30.87 | -- | -32.86 | -- | -- | -- | -807.62 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Ginkgo Bioworks Holdings Inc | 217.95m | -651.19m | 412.70m | 1.22k | -- | 0.4776 | -- | 1.89 | -12.90 | -12.90 | 4.29 | 15.03 | 0.1243 | -- | 5.01 | 178,941.70 | -37.13 | -- | -40.39 | -- | 80.94 | -- | -298.78 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Tango Therapeutics Inc | 43.38m | -123.40m | 421.08m | 140.00 | -- | 1.84 | -- | 9.71 | -1.15 | -1.15 | 0.4041 | 2.13 | 0.1112 | -- | -- | 309,885.70 | -31.62 | -- | -35.28 | -- | -- | -- | -284.43 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 435.85m | 116.00 | -- | -- | -- | 17.08 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Aura Biosciences Inc | 0.00 | -83.22m | 443.97m | 88.00 | -- | 2.55 | -- | -- | -1.73 | -1.73 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -43.22 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| MeiraGTx Holdings PLC | 13.93m | -88.18m | 457.70m | 389.00 | -- | 4.81 | -- | 32.86 | -1.30 | -1.30 | 0.2123 | 1.23 | 0.0492 | -- | 1.08 | 33,243.44 | -31.12 | -26.40 | -39.74 | -32.66 | -7.72 | -- | -633.05 | -420.70 | -- | -- | 0.4324 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 458.05m | 180.00 | -- | 1.75 | -- | 2.86 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| OmniAB Inc | 20.41m | -63.02m | 463.20m | 106.00 | -- | 1.62 | -- | 22.70 | -0.6227 | -0.6227 | 0.2017 | 2.43 | 0.0564 | -- | 4.24 | 192,537.70 | -17.43 | -- | -18.43 | -- | -- | -- | -308.78 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Allogene Therapeutics Inc | 43.00k | -283.43m | 463.38m | 232.00 | -- | 0.9984 | -- | 10,776.17 | -1.53 | -1.53 | 0.0002 | 2.21 | 0.00007 | -- | -- | 185.34 | -43.56 | -28.46 | -46.04 | -30.21 | -- | -- | -659,137.20 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Data as of Nov 25 2024. Currency figures normalised to Tango Therapeutics Inc's reporting currency: US Dollar USD
44.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 07 Nov 2024 | 10.63m | 9.92% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 9.38m | 8.75% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 5.02m | 4.69% |
| Southpoint Capital Advisors LPas of 30 Sep 2024 | 5.00m | 4.67% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.91m | 3.65% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.51m | 3.27% |
| Citadel Advisors LLCas of 30 Sep 2024 | 2.69m | 2.51% |
| Balyasny Asset Management LPas of 30 Sep 2024 | 2.69m | 2.51% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.32m | 2.16% |
| Adage Capital Management LPas of 30 Sep 2024 | 2.29m | 2.14% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
